Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript

View original at finance.yahoo.com
D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript Image source: The Motley Fool. Date Thursday, November 14, 2024 at 8 a.m. ET Call participants Chief Executive Officer — Alan Baratz Chief Financial Officer — John Markovich Need a quote from a Motley Fool analyst?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • D-Wave's intellectual property covers both annealing AND gate model technologies, with majority of 240+ US granted patents covering both

    80% confidence
  • D-Wave goal is to be the first independent public quantum company to achieve sustained profitability

    80% confidence
  • D-Wave is the only quantum company offering formal SLAs

    80% confidence
  • Q4 revenue expected to improve over Q3

    80% confidence
  • D-Wave aims to achieve profitability with substantially less funding than competitors

    80% confidence
  • D-Wave shows versatility once thought limited to gate-based systems

    80% confidence
  • Advantage system with 5,000 qubits is the largest and most powerful quantum computer in the world

    80% confidence
  • NTT DOCOMO deployment achieved 15% reduction in network congestion, solving in 40 seconds vs 27 hours classical compute

    80% confidence
  • Advantage 2 will be added to Leap cloud service sooner rather than later

    80% confidence
  • Europe is ahead of US in likely government quantum deployments

    80% confidence
  • FY2024 adjusted EBITDA loss will be less than $54.3M

    80% confidence
  • Work by Chinese researchers shows only quantum system factoring non-trivial numbers is D-Wave annealing

    80% confidence
  • Q4 bookings expected to improve over Q3

    80% confidence
  • D-Wave's annealing systems are one of few quantum technologies used by organizations to run production use cases to gain business value

    80% confidence
  • Leap Quantum Cloud Service has achieved 99.9%+ availability over 2 years

    80% confidence
  • The long sought killer use case for quantum is quantum optimization, and evidence shows only annealing quantum systems will deliver speed-up on quantum optimization

    80% confidence
  • D-Wave does not sell to China or Chinese companies due to US and Canada government restrictions

    80% confidence
  • D-Wave is the only quantum computing company with commercial production deployments

    80% confidence
  • Production apps generate high $100Ks to $1M+ annual recurring QCaaS revenue

    80% confidence
  • Go-to-market hiring expected to complete by mid-Q1 2025

    80% confidence

Data points we hold from this source

D-Wave Quantum Inc. · gross margin gaap55.8 percent
D-Wave Quantum Inc. · gross margin non gaap67.2 percent
D-Wave Quantum Inc. · lincoln park equity line remaining49.9 million_USD
D-Wave Quantum Inc. · bookings7.4 million_USD
D-Wave Quantum Inc. · adjusted ebitda loss13.8 million_USD
D-Wave Quantum Inc. · atm program remaining79.1 million_USD
D-Wave Quantum Inc. · eps-0.51 USD
D-Wave Quantum Inc. · cash30 million_USD
D-Wave Quantum Inc. · total customers132 customers
D-Wave Quantum Inc. · commercial customers76 customers
D-Wave Quantum Inc. · commercial revenue decrease0.2 million_USD
D-Wave Quantum Inc. · forbes global 2000 customers27 customers
D-Wave Quantum Inc. · research revenue increase0.6 million_USD
D-Wave Quantum Inc. · qcaas revenue5.1 million_USD
D-Wave Quantum Inc. · professional services revenue0.3 million_USD
D-Wave Quantum Inc. · patent count240 patents
D-Wave Quantum Inc. · debt0 million_USD
D-Wave Quantum Inc. · net loss66.7 million_USD
D-Wave Quantum Inc. · government revenue increase0.8 million_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com